Cover image of MPS II medicines review protocol


Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Medicines review protocol

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date: 
4 July 2019
Publication type: 
Intended audience: 
General public

The reviewers will use data sources specified in this document and results of stakeholder consultation to describe:

  • prevalence of mucopolysaccharidosis type II (MPS II) in Australia
  • management of MPS II in comparison to Life Saving Drugs Program (LSDP) guidelines
  • clinical and comparative effectiveness and safety of medicines
  • relevant patient-based outcomes
  • value for money of LSDP treatment for MPS II
  • use of the LSDP MPS II medicines
  • developing technologies that may impact future access.